12:00 AM
 | 
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-KIR: Phase IIa start

Innate will soon begin the open-label, French Phase IIa IPH 2101-201 trial to evaluate 0.2 or 2 mg/kg IV IPH 2101...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >